Empower Advisory Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251K Sell
3,205
-105
-3% -$7.16K ﹤0.01% 470
2026
Q1
$214K Sell
3,310
-4,908
-60% -$346K ﹤0.01% 486
2025
Q4
$553K Buy
8,218
+4,109
+100% +$276K ﹤0.01% 327
2025
Q3
$301K Sell
4,109
-341
-8% -$22.7K ﹤0.01% 429
2025
Q2
$231K Hold
4,450
﹤0.01% 455
2025
Q1
$284K Sell
4,450
-1,257
-22% -$73K ﹤0.01% 408
2024
Q4
$273K Hold
5,707
﹤0.01% 429
2024
Q3
$327K Sell
5,707
-161
-3% -$9.23K ﹤0.01% 383
2024
Q2
$307K Hold
5,868
﹤0.01% 389
2024
Q1
$239K Sell
5,868
-1,519
-21% -$56.9K ﹤0.01% 461
2023
Q4
$273K Hold
7,387
﹤0.01% 413
2023
Q3
$282K Hold
7,387
﹤0.01% 394
2023
Q2
$266K Hold
7,387
﹤0.01% 412
2023
Q1
$286K Buy
+7,387
New +$346K ﹤0.01% 394

Other funds holding HALO

Empower Advisory Group's HALO Position: Q2 2026 in Review

Empower Advisory Group reduced its Halozyme (HALO) stake by 3.2% in Q2 2026, selling an estimated $7.16K and leaving 3,205 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Empower Advisory Group first reported a position in HALO in Q1 2023 and has held it in 14 quarters since. The position peaked at $553K in Q4 2025. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Empower Advisory Group held 3,205 shares of Halozyme worth $251K as of Q2 2026.
  • Empower Advisory Group sold 105 Halozyme shares in Q2 2026, an estimated $7.16K.
  • Halozyme made up ﹤0.01% of Empower Advisory Group's portfolio in Q2 2026, its #470 holding.
  • Empower Advisory Group first reported a position in Halozyme in Q1 2023 and has held it in 14 quarters since.
  • Empower Advisory Group's Halozyme position peaked at $553K in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Empower Advisory Group's 13F filing for Q2 2026, filed 12 Aug 2026.